SEC22C

Across TCGA pan-cancer cohorts, SEC22C RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of SEC22C’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SEC22C RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SEC22C is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

HNSC, THCA, and KIRC are the cancer types where SEC22C tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SEC22C RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.654	<.001	11	view →
THCA	Male	III,IV	−0.717	<.001	10	view →
KIRC	All	II,III,IV	−0.460	<.001	10	view →
LUSC	Female	II,III,IV	−1.002	<.001	9	view →
LUAD	Female	III,IV	−0.905	<.001	9	view →
LIHC	Female	II,III,IV	+0.897	<.001	9	view →
BRCA	Female	All	−0.229	<.001	4	view →
CHOL	All	All	+1.468	<.001	3	view →
UCEC	All	All	−0.581	.001	2	view →
PRAD	All	All	+0.470	<.001	2	view →
KICH	All	All	−0.426	.003	2	view →
COAD	Male	All	+0.306	.029	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

SEC22C–HNSC

Open the HNSC breakdown →